BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34393062)

  • 1. Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell Lung Cancer.
    Umemura S; Chen V; Chahine JJ; Kallakury B; Zhao X; Lee H; Avantaggiati ML; He Y; Wang C; Giaccone G
    Clin Lung Cancer; 2022 Mar; 23(2):e140-e147. PubMed ID: 34393062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse high intensity PD-L1 staining in thymic epithelial tumors.
    Padda SK; Riess JW; Schwartz EJ; Tian L; Kohrt HE; Neal JW; West RB; Wakelee HA
    J Thorac Oncol; 2015 Mar; 10(3):500-8. PubMed ID: 25402569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
    Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
    PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
    Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
    Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HSP27 and 70 expression in thymic epithelial tumors and benign thymic alterations: diagnostic, prognostic and physiologic implications.
    Janik S; Schiefer AI; Bekos C; Hacker P; Haider T; Moser J; Klepetko W; Müllauer L; Ankersmit HJ; Moser B
    Sci Rep; 2016 Apr; 6():24267. PubMed ID: 27097982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment serum neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios: Two tumor-related systemic inflammatory markers in patients with thymic epithelial tumors.
    Wang L; Ruan M; Yan H; Lei B; Sun X; Chang C; Liu L; Xie W
    Cytokine; 2020 Sep; 133():155149. PubMed ID: 32512341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.
    Owen D; Chu B; Lehman AM; Annamalai L; Yearley JH; Shilo K; Otterson GA
    J Thorac Oncol; 2018 Aug; 13(8):1204-1212. PubMed ID: 29702286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and clinicopathological roles of programmed death-ligand 1 (PD-L1) expression in thymic epithelial tumors: A meta-analysis.
    Koh HM; Jang BG; Lee HJ; Hyun CL
    Thorac Cancer; 2020 Nov; 11(11):3086-3098. PubMed ID: 32926538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High levels of expression of Trop-2 in thymic epithelial tumors.
    Yeung V; Zaemes J; Yeh J; Giancarlo C; Ahn J; Reuss JE; Kallakury BV; Liu SV; Duttargi A; Khan G; Kim C
    Lung Cancer; 2023 Oct; 184():107324. PubMed ID: 37573703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and clinical significance of KIT(CD117) expression in thymic epithelial tumors in China.
    Song N; Chen G; Zhang P; Liu M; He WX; Jiang GN
    Asian Pac J Cancer Prev; 2012; 13(6):2745-8. PubMed ID: 22938452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation.
    Bellissimo T; Ganci F; Gallo E; Sacconi A; Tito C; De Angelis L; Pulito C; Masciarelli S; Diso D; Anile M; Petrozza V; Giangaspero F; Pescarmona E; Facciolo F; Venuta F; Marino M; Blandino G; Fazi F
    Mol Cancer; 2017 May; 16(1):88. PubMed ID: 28486946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Death-ligand 1 (PD-L1) Expression in Thymic Epithelial Tumors.
    Bedekovics J; Beke L; Mokanszki A; Szilagyi S; Mehes G
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):1-9. PubMed ID: 30499814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LINC00174 is a novel prognostic factor in thymic epithelial tumors involved in cell migration and lipid metabolism.
    Tito C; Ganci F; Sacconi A; Masciarelli S; Fontemaggi G; Pulito C; Gallo E; Laquintana V; Iaiza A; De Angelis L; Benedetti A; Cacciotti J; Miglietta S; Bellenghi M; Carè A; Fatica A; Diso D; Anile M; Petrozza V; Facciolo F; Alessandrini G; Pescarmona E; Venuta F; Marino M; Blandino G; Fazi F
    Cell Death Dis; 2020 Nov; 11(11):959. PubMed ID: 33161413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and validation of DNA methylation markers for overall survival prognosis in patients with thymic epithelial tumors.
    Li S; Yuan Y; Xiao H; Dai J; Ye Y; Zhang Q; Zhang Z; Jiang Y; Luo J; Hu J; Chen C; Wang G
    Clin Epigenetics; 2019 Mar; 11(1):38. PubMed ID: 30832724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated CRP levels predict poor outcome and tumor recurrence in patients with thymic epithelial tumors: A pro- and retrospective analysis.
    Janik S; Bekos C; Hacker P; Raunegger T; Ghanim B; Einwallner E; Beer L; Klepetko W; Müllauer L; Ankersmit HJ; Moser B
    Oncotarget; 2017 Jul; 8(29):47090-47102. PubMed ID: 28514756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prognostic Value of Tumor Mutation Burden and Immune Cell Infiltration in Thymic Epithelial Tumors.
    Du H; Xie S; Guo W; Zhang W; Che J; Zhu L; Hang J
    Ann Clin Lab Sci; 2021 Jan; 51(1):44-54. PubMed ID: 33653780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of mesothelin in thymic carcinoma and its potential therapeutic significance.
    Thomas A; Chen Y; Berman A; Schrump DS; Giaccone G; Pastan I; Venzon DJ; Liewehr DJ; Steinberg SM; Miettinen M; Hassan R; Rajan A
    Lung Cancer; 2016 Nov; 101():104-110. PubMed ID: 27794397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed death-ligand 1 expression profiling in thymic epithelial cell tumors: Clinicopathological features and quantitative digital image analyses.
    Ishihara S; Okada S; Ogi H; Kodama Y; Shimomura M; Tsunezuka H; Itoh K; Marx A; Inoue M
    Lung Cancer; 2020 Jul; 145():40-47. PubMed ID: 32402921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors.
    Tateo V; Manuzzi L; De Giglio A; Parisi C; Lamberti G; Campana D; Pantaleo MA
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tropomyosin-related Kinase B Is Potentially a Biomarker of Prognosis and Therapeutic Target for Malignant Thymic Epithelial Tumors.
    Ozono K; Onishi H; Iwamoto N; Nakamura K; Miyoshi K; Nakamura M; Oda Y
    Anticancer Res; 2022 Aug; 42(8):3779-3787. PubMed ID: 35896228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.